Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hana A. Al-Abdulkarim"'
Autor:
Yazed AlRuthia, Ohud H. Bahari, Suliman Alghnam, Ali M. Alrumaih, Hassan Asiri, Mohammed Alshammari, Mansour Alhowimel, Hana A. Al-Abdulkarim
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
BackgroundThe advent of Basaglar®, which is a biosimilar insulin glargine formulation for Lantus® has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeuti
Externí odkaz:
https://doaj.org/article/acc1640056ac48d2a0c2b6f1aabca793
Autor:
Yazed AlRuthia, Haya F. Al-Salloum, Omar A. Almohammed, Amani S. Alqahtani, Hana A. Al-Abdulkarim, Yousef M. Alsofayan, Sami S. Almudarra, Sara H. AlQahtani, Abdullah Almutlaq, Khaled Alabdulkareem, Bander Balkhi, Hamoud T. Almutairi, Abdullah S. Alanazi, Yousif A. Asiri
Publikováno v:
Vaccines, Vol 10, Iss 2, p 323 (2022)
Background: Saudi Arabia expedited the approval of some COVID-19 vaccines and launched mass vaccination campaigns. The aim of this study was to describe the demographics of vaccinated COVID-19 cases and compare the mortality rates of COVID-19 cases w
Externí odkaz:
https://doaj.org/article/397e753b7a404bc09a44bd786820ea87
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 55-64 (2020)
As the Pharmacy and Therapeutics (P&T) committee acts as an advisory committee on therapeutic options, it is important during pandemics, such as the current Coronavirus disease 2019 pandemic, to quickly search the evidence, be able to select the most
Externí odkaz:
https://doaj.org/article/c853cecd955b4add930c38163b1c65b4
Autor:
Fahad Alsabaan, Abdulaziz Altowaijri, Mai AlSaqa’aby, Mohammed S. Aljamal, Saud Alsifri, Yazed AlRuthia, Bander Balkhi, Ali M. Alrumaih, Hana Abdullah Al-Abdulkarim, Sulaiman A. Alrashed
Publikováno v:
Health Policy and Technology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4c0ed25d6f65b5592343875938267b
https://doi.org/10.1016/j.hlpt.2020.10.008
https://doi.org/10.1016/j.hlpt.2020.10.008
Autor:
Sherine Ismail, Consuela Cheriece Yousef, Murtada Halim, Hind Almodaimegh, Hana Abdullah Al-Abdulkarim, Mansour Alhowimel, Laila Carolina Abu Esba
Publikováno v:
Health Policy and Technology. 10:100500
Introduction Fixed-dose combinations (FDCs) are marketed with the promise of optimum patient adherence, improvement in the disease management and lower cost. P&T decision makers commonly overlook some factors that may render a FDC a poor choice. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::465079e0145b26a5a063046bd6fb24dd
https://doi.org/10.1016/j.hlpt.2021.02.006
https://doi.org/10.1016/j.hlpt.2021.02.006